Who
Jane Henderson
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Apogee Therapeutics; Director, Akero Therapeutics; Director, CARGO Therapeutics; Director, IVERIC bio; Chief Financial Officer, Invivyd; Director, Sesen Bio; Sr. V.P. & CFO, Corp. Dev., Voyager Therapeutics; Chief Financial Officer & CBO, Panacos Pharmaceuticals.
In numbers
- Trades disclosed
- 125
- Buys
- 1
- Sells
- 20
- Bought
- $24K
- Sold
- $7.3M
- Companies
- 8
- Companies where not an officer
- 4
- First trade
- 3 Jan 2008
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —158,371 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —175,345 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —124,962 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —175,345 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —124,962 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —83,690 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —83,690 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —158,371 | filing |
| 24 Jul 2026filed 24 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code G | —15,000 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code G | —15,000 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K811 at $81.02 | filing |
| 1 May 2026filed 4 May 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $74K900 at $82.60 | filing |
| 1 May 2026filed 4 May 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K289 at $83.16 | filing |
| 1 May 2026filed 4 May 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K811 at $81.02 | filing |
| 1 May 2026filed 4 May 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $74K900 at $82.60 | filing |
| 1 May 2026filed 4 May 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K289 at $83.16 | filing |
| 16 Apr 2026filed 17 Apr 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $180K2,000 at $90.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $180K2,000 at $90.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $76K900 at $84.46 | filing |
| 1 Apr 2026filed 3 Apr 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $94K1,100 at $85.46 | filing |
News
No headline names them, or the companies they trade most, lately.